Gene polymorphisms in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 1, 2008, Pages 1-8

  Franekova, Maria ^a   Halasova, Erika ^a   Bukovska, Eva ^a   Luptak, Jan ^a   Dobrota, Dusan ^a  

^a University Teaching Hospital in Martin   (Slovakia)

Author keywords

Bladder cancer; Polymorphisms

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; CYTOCHROME P450; GLUTATHIONE TRANSFERASE M1; MYELOPEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFOTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

AMINO ACID SUBSTITUTION; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CIGARETTE SMOKING; DETOXIFICATION; DNA DAMAGE; DNA REPAIR; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HUMAN; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW;

AGED; DNA REPAIR; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 37649019300     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.10.011     Document Type: Review

References (105)

1. Ferlay J., Bray F., Pisani P., et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1,0. IARC Cancer Base No. 5 (2001), IARC Press, Lyon (France)
2. Sternberg C.N., and Calabro F. Chemotherapy and management of bladder tumours. BJU Int 85 (2000) 599-610
3. Huncharek M., Geschwind J.F., Witherspoon B., et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: A meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53 (2000) 676-680
4. Stewart B.W., and Kleihus P. World cancer report (2003), IARC Press, Lyon, France
5. Stern M.C., Johnson L.R., Bell D.A., et al. XPD Codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 1004-1011
6. Sanyal S., Festa F., Sakano S., et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25 (2004) 729-734
7. Miller M.C., Mohrenweiser H.W., and Bell D.A. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120 (2001) 269-280
8. Hein D.W., Doll M.A., Fretland A.J., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9 (2000) 29-42
9. Butcher N.J., Arulpragasam A., Goh H.L., et al. Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 387 (2005) 119-127
10. Daly A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17 (2003) 27-41
11. Mittal R.D., Srivastava D.S.L., and Mandhani A. NAT2 gene polymorphism in bladder cancer: A study from North India. Int Braz J Urol 30 (2004) 279-288
12. Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Publ 148 (1999) 251-270
13. Gu J., Liang D., Wang Y., et al. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 581 (2005) 97-104
14. Cascorbi I, Roots I, Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: Significantly reduced risk in subjects with NAT1*10. Cancer Res 61:5051-6.
15. Schnakenberg E., Lustig M., Breuer R., et al. Gender-specific effects of NAT2 and GSTM1 in bladder cancer. Clin Genet 57 (2000) 270-277
16. Vineis P., Marinelli D., Autrup H., et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 10 (2001) 1249-1252
17. Inatomi H., Katoh T., Kawamoto T., et al. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6 (1999) 446-454
18. Hung R.J., Boffetta P., Brennan P., et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110 (2004) 598-604
19. Giannakopoulos X., Charalabopoulos K., Baltogiannis D., et al. The role of N-acetyltranferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. Anticancer Res 22 (2002) 3801-3804
20. Ma Q.W., Lin G.F., Chen J.G., et al. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: Occupational and non-occupational bladder cancer patient groups. Biomed Environ Sci 17 (2004) 291-298
21. Hsieh F.I., Pu Y.S., Chern H.D., et al. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 81 (1999) 537-541
22. Marcus P.M., Hayes R.B., Vineis P., et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 9 (2000) 461-467
23. Lu C.-M., Chung M.-C., Huang C.-H., et al. Interaction effect in bladder cancer between N-acetyltransferase 2 genotype and alcohol drinking. Urol Int 75 (2005) 360-364
24. Schnakenberg E., Breuer R., Werdin R., et al. Susceptibility genes: GSTM1 and GSTM3 as genetic risk factors in bladder cancer. Cytogenet Cell Genet 91 (2000) 234-238
25. Strange R.C., Spiteri M.A., Ramachandran S., et al. Glutathione-S-transferase family of enzymes. Mutat Res 482 (2001) 21-26
26. Habdous M., Siest G., Herbeth B., et al. Glutathione S-transferases genetic polymorphisms and human diseases: Overview of epidemiological studies. Ann Biol Clin (Paris) 62 (2004) 15-24
27. Jeong H.J., Kim H.J., Seo I.Y., et al. Association between glutathione S-transferase M1 and T1 polymorphisms and increased risk for bladder cancer in Korean smokers. Cancer Lett 202 (2003) 193-199
28. Ye Z., and Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis. Eur J Cancer 41 (2005) 980-989
29. Srivastava D.S., Mandhani A., Mittal B., et al. Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int 95 (2005) 170-173
30. McLellan R.A., Oscarson M., Alexandrie A.-K., et al. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 52 (1997) 958-965
31. Aktas D., Ozen H., Atsu N., et al. Glutathione S-transferase M1 gene polymorphism in bladder cancer patients: A marker for invasive bladder cancer?. Cancer Genet Cytogenet 125 (2001) 1-4
32. Lee S.-J., Cho S.-H., Park S.K., et al. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 177 (2002) 173-179
33. García-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
34. Karagas M.R., Park S., Warren A., et al. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: A population-based study. Cancer Lett 219 (2005) 63-69
35. Salagovic J., Kalina I., Habalova V., et al. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. Physiol Res 48 (1999) 465-471
36. Abdel-Rahman S.Z., Anwar W.A., Abdel-Aal W.E., et al. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 22 (1998) 129-138
37. Srivastava D.S., Kumar A., Mittal B., et al. Polymorphism of GSTM1 and GSTT1 genes in bladder cancer: A study from North India. Arch Toxicol 78 (2004) 430-434
38. Harries L.W., Stubbins M.J., Forman D., et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18 (1997) 641-644
39. Srivastava D.S., Mishra D.K., Mandhani A., et al. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol 48 (2005) 339-344
40. Mittal R.D., and Srivastava D.S. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev 6 (2005) 6-9
41. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 36 (2004) 639-654
42. Bock C.H., Wenzlaff A.S., Cote M.L., et al. NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: Results from a population-based study. Carcinogenesis 26 (2005) 381-386
43. Park S.-J., Zhao H., Spitz M.R., et al. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536 (2003) 131-137
44. Choi J.Y., Lee K.M., Cho S.H., et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13 (2003) 349-355
45. Gamage N., Barnett A., Hempel N., et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90 (2006) 5-22
46. Nowell S., and Falany C.N. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 25 (2006) 1673-1678
47. Raftogianis R.B., Wood T.C., Otterness D.M., et al. Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239 (1997) 298-304
48. Zheng L., Wang Y., Schabath M.B., et al. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: A case-control study. Cancer Lett 202 (2003) 61-69
49. Kantarci O.H., Lesnick T.G., Yang P., et al. Myeloperoxidase-463 (G->A) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc 77 (2002) 17-22
50. Schabath M.B., Spitz M.R., Hong W.K., et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 37 (2002) 35-40
51. Hung R.J., Boffetta P., Brennan P., et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25 (2004) 973-978
52. Fishbain D.A., Fishbain D., Lewis J., et al. Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time?. A structured review. Pain Med 5 (2004) 81-93
53. Anwar W.A., Abdel-Rahman S.Z., El-Zein R.A., et al. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17 (1996) 1923-1929
54. Brockmoller J., Cascorbi I., Kerb R., et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56 (1996) 3915-3925
55. Sharova N.P. How does a cell repair damaged DNA?. Biochemistry (Mosc) 70 (2005) 275-291
56. Goode E.L., Ulrich C.M., and Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 1513-1530
57. Wu X., Gu J., Grossman H.B., et al. Bladder cancer predisposition: A multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78 (2006) 464-479
58. Blankenburg S., Konig I.R., Moessner R., et al. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: A case-control study. Carcinogenesis 26 (2005) 1085-1090
59. Park C.-J., and Choi B.-S. The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. FEBS J 273 (2006) 1600-1608
60. Sugimura T., Kumimoto H., Tohnai I., et al. Gene-environment interaction involved in oral carcinogenesis: Molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 35 (2006) 11-18
61. Schabath M.B., Delclos G.L., Grossman H.B., et al. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 14 (2005) 878-884
62. Vogel U., Overvad K., Wallin H., et al. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 222 (2005) 67-74
63. Terry M.B., Gammon M.D., Zhang F.F., et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 13 (2004) 2053-2058
64. Yu H.-P., Wang X.-L., Sun X., et al. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytogenet 154 (2004) 10-15
65. Sakano S., Kumar R., Larsson P., et al. A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int 97 (2005) 847-851
66. Sak S.C., Barrett J.H., Paul A.B., et al. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. Br J Cancer 92 (2005) 2262-2265
67. Yeh C.-C., Sung F.-C., Tang R., et al. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: A case-control study in Taiwan. BMC Cancer 5 (2005) 12
68. Moreno V., Gemignani F., Landi S., et al. Polymorphisms in genes of nucleotide and base excision repair: Risk and prognosis of colorectal cancer. Clin Cancer Res 1 (2006) 2101-2108
69. Jin M.J., Chen K., Song L., et al. The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population. Cancer Genet Cytogenet 163 (2005) 38-43
70. Smith T.R., Miller M.S., Lohman K., et al. Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190 (2003) 183-190
71. Figueiredo J.C., Knight J.A., Briollais L., et al. Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 13 (2004) 583-591
72. Jacobsen N.R., Raaschou-Nielsen O., Nexø B., et al. XRCC3 polymorphisms and risk of lung cancer. Cancer Lett 213 (2004) 67-72
73. Skjelbred C.F., Sæbø M., Wallin H., et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer 6 (2006) 67-75
74. Caldecott K.W. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2 (2003) 955-969
75. Qu T., and Morimoto K. X-ray repair cross-complementing group 1 polymorphisms and cancer risks in Asian populations: A mini review. Cancer Detect Prev 29 (2005) 215-220
76. Kang D. Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. J Biochem Mol Biol 36 (2003) 28-34
77. Kelsey K.T., Park S., Nelson H.H., et al. A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 1337-1341
78. Hung R.J., Hall J., Brennan P., et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am J Epidemiol 162 (2005) 925-942
79. Hu Z., Ma H., Chen F., et al. XRCC1 polymorphisms and cancer risk: A meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 14 (2005) 1810-1818
80. Shen M., Hung R.J., Brennan P., et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in Northern Italy. Cancer Epidemiol Biomarkers Prev 12 (2003) 1234-1240
81. Stern M.C., Umbach D.M., van Gils C.H., et al. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 10 (2001) 125-131
82. Stern M.C., Umbach D.M., Lunn R.M., et al. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 939-943
83. Aggarwal B.B., Shishodia S., Ashikawa K., et al. The role of TNF and its family members in inflammation and cancer: Lessons from gene deletion. Curr Drug Targets Inflamm Allergy 1 (2002) 327-341
84. Kim E.-U., Jeong P., Quan C., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
85. Jeong P., Kim E.-J., Kim E.-G., et al. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology 64 (2004) 1052-1056
86. Marsh H.P., Haldar N.A., Bunce M., et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 89 (2003) 1096-1101
87. Chan A.O.O. E-cadherin in gastric cancer. World J Gastroenterol 12 (2006) 199-203
88. Tsukino H., Kuroda Y., Nakao H., et al. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 195 (2003) 53-58
89. Zhang X., Ma X., Zhu Q.G., et al. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 170 (2003) 1379-1382
90. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93 (2001) 1062-1074
91. Johne A., Roots I., and Brockmoller J. A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 68-70
92. Sanyal S., Festa F., Sakano S., et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25 (2004) 729-734
93. Gasco M., Shami S., and Crook T. The p53 pathway in breast cancer. Breast Cancer Res 4 (2002) 70-76
94. Soulitzis N., Sourvinos G., Dokianakis D.N., et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179 (2002) 175-183
95. Chen W.C., Tsai F.J., Wu J.Y., et al. Distributions of p53 codon 72 polymorphism in bladder cancer-Proline form is prominent in invasive tumor. Urol Res 28 (2000) 293-296
96. Toruner G.A., Ucar A., Tez M., et al. P53 codon 72 polymorphism in bladder cancer-No evidence of association with increased risk or invasiveness. Urol Res 29 (2001) 393-395
97. Mabrouk I., Baccouche S., El-Abed R., et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010 (2003) 764-770
98. Biros E., Kalina I., Salagovic J., et al. p53 single nucleotide polymorphisms and bladder cancer. Neoplasma 47 (2000) 303-306
99. Chen Y.C., Xu L., Guo Y.L., et al. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: A preliminary study. Biomarkers 9 (2004) 386-394
100. Wang L., Habuchi T., Takahashi T., et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 97 (2002) 787-790
101. Berman D.M., Wang Y., Liu Z., et al. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64 (2004) 6820-6826
102. Cortessis V.K., Siegmund K., Xue S., et al. A case-control study of cyclin D1 CCND1 870A→G polymorphism and bladder cancer. Carcinogenesis 24 (2003) 1645-1650
103. Ito M., Habuchi T., Watanabe J., et al. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology 64 (2004) 74-78
104. Karagas M.R., Park S., Nelson H.H., et al. Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study. Int J Hyg Environ Health 208 (2005) 321-327
105. Lin J., Spitz M.R., Wang Y., et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: A case-control study. Carcinogenesis 25 (2004) 1639-1647